

Digital Health Technologies for Metabolic Disorders in Older Adults: A Scoping Review Protocol

Panitda Huynh¹, Elgar Fleisch^{2,4}, Michael Brändle³, Tobias Kowatsch^{*1,4,5}, Mia Jovanova^{*1}

*= shared last authorship

ORCID:

Panitda Huynh (0000-0002-1169-2271)

Elgar Fleisch (0000-0002-4842-1117)

Michael Brändle (0000-0002-3228-0313)

Tobias Kowatsch (0000-0001-5939-4145)

Mia Jovanova (0000-0003-3634-4449)

Affiliations:

¹ School of Medicine, University of St. Gallen, St. Gallen, Switzerland

² Institute of Technology Management, University of St. Gallen, St. Gallen, Switzerland

³ Internal Medicine & Endocrinology/Diabetes, Kantonsspital St. Gallen, St. Gallen, Switzerland

⁴ Centre for Digital Health Interventions, Department of Management, Technology and Economics, ETH Zürich, Zurich, Switzerland

⁵ Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland

**corresponding author: mia.jovanova@unisg.ch

Keywords: aging; older adults; digital health technologies; metabolic disorders; elderly care; burden; healthy aging

Abstract

Introduction: Metabolic disorders (type 2 diabetes, insulin resistance, hyperglycemia, obesity, hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and metabolic syndrome) are leading causes of mortality and disability worldwide and disproportionately affect older adults relative to those younger. Digital health technologies (DHTs), such as patient monitoring, digital diagnostics, and digital therapeutics, emerge as promising tools for navigating health in day-to-

32 day life. However, their role in targeting metabolic disorders, particularly among a key demo-
33 graphic of older adults, is not yet fully understood. Thus, this work aims to scope the use of
34 DHTs in managing metabolic health disorders among older adults.

35 **Methods and Analysis:** We will conduct a scoping review following the recommended frame-
36 work by Arksey and O'Malley (1). Our search will focus on three primary concepts: metabolic
37 disorders, DHTs, and older adults. We plan to search five online databases—Cochrane, Embase,
38 PubMed, Scopus, and Web of Science—to identify original research articles published between
39 January 2014 and January 2024. Two reviewers will independently screen articles for inclusion
40 based on predetermined criteria, and a separate reviewer will resolve conflicts. Data will be ex-
41 tracted using a standardized form, and the findings will be synthesized and reported qualitatively
42 and quantitatively.

43 **Ethics and dissemination.** No ethics approval is required for this protocol and scoping review,
44 as data will be used only from published studies with appropriate ethics approval. Results will be
45 disseminated in a peer-reviewed publication.

46

47 This protocol has been preregistered on OSF Repository at: <https://osf.io/9s8fm>.

48

49 **Strengths and limitations of this study**

- 50 • To our knowledge, this scoping review is the first to scope the landscape of DHTs for tar-
51 geting metabolic disorders among older adults.
- 52 • We apply the DHT Ecosystem Categorization for a more standardized overview of the
53 peer-reviewed empirical literature across multiple databases and follow rigorous scoping
54 review reporting guidelines.
- 55 • Consistent with the nature of scoping reviews, our study does not include an assessment
56 of the quality of the included studies, only involves studies in English, and does not in-
57 clude non-peer reviewed industry reports, which may also provide relevant information.
- 58 • Since our pre-existing definition of metabolic disorders focuses on various pre-defined
59 major conditions, there exists a possibility that we may not comprehensively capture all
60 possible instances of metabolic disorders among older adults.

61

62 **1 BACKGROUND**

63 Non-communicable diseases (NCDs) are primary drivers of morbidity and mortality globally,
64 with estimates by the World Health Organization (WHO) to surpass 15 million premature deaths
65 attributed to NCDs per year (2). Over 50% of cases of NCDs is attributed to a growing preva-
66 lence of metabolic disorders; namely type 2 diabetes mellitus (T2DM), hypertension (HTN), hy-
67 perlipidaemia (HLD), obesity and more recently, non-alcoholic fatty liver disease (NAFLD)
68 (2,3). Metabolic disorders are more prevalent among older adults versus younger populations, in
69 part due to age-related physiological changes in metabolism and hormones, cumulative effects of
70 lifestyle factors (e.g., nutrition, sleep, and physical activity), and susceptibility to related comor-
71 bidities (e.g. cardiovascular diseases, diabetes) (4–6). Metabolic disorders are often defined as
72 conditions that affect the body’s conversion of food into energy and the ability to eliminate waste
73 (7). Key factors contributing to the risk of metabolic disorders are the intake of an unhealthy diet,
74 a sedentary lifestyle, and insufficient exercise, among others (7).

75 Nonpharmaceutical intervention efforts that target lifestyle factors are a promising approach to
76 navigating metabolic disorders (7), and increasingly involve digital health technologies (DHTs)–
77 which are defined by the Food and Drug Administration (FDA) as “computing platforms, con-
78 nectivity, software, and sensors used for health care and related uses (8,9). Notably, DHTs may
79 help older adults and caregivers manage aspects of metabolic health in day-to-day life (vs. in the
80 clinic) and overcome barriers of more traditional health assessments (10), e.g., by reducing costs
81 associated with in-person visits for patients and reducing burden for healthcare professionals,
82 enhanced experience for patients, as well as improved mental health for healthcare professionals
83 (11). However, DHTs are rapidly evolving and are often studied under inconsistent terminologies
84 (10,12,13). This heterogeneity complicates efforts to synthesize evidence on their prevalence and
85 potential impact in metabolic and related health contexts (13,14).

86 In response, the international organization overseeing DHT implementation in healthcare, the
87 Digital Therapeutics (DTx) Alliance, has called for systematic overviews of DHTs and a shared
88 language to facilitate standardization (8,9). To this end, DTx Alliance has formally categorized
89 DHTs according to their intended purpose in five categories (see Table 1): (i) promoting health &
90 wellness, (ii) patient monitoring, (iii) care support, (iv) digital diagnostics, and (v) digital thera-
91 peutics (15). These classification guidelines aim to help map a wide range of existing products by
92 their intended use and offer a more consistent and actionable language for different stakeholders,
93 including researchers, medical professionals, patients, and policymakers (8).

94 In line with recent calls for systematic synthesis of DHTs in healthcare (13,16–18), several scop-
 95 ing reviews have recently overviewed the role of digital health applications in navigating NCDs
 96 (14,19–21), health promotion (22), and their associated barriers and facilitators (19–21) among
 97 older adults. In parallel, a separate line of work has begun to review the scope of interventions in
 98 promoting behaviors related to metabolic health, such as physical activity and nutrition among
 99 older adults (5,23). However, this work has not yet considered specific the role of DHTs in the
 100 context of metabolic health. Bridging these disparate lines of work, we aim to scope DHTs in
 101 metabolic disorders among older adults, encompassing a twofold objective. First, following
 102 guidelines from the DTx Alliance, we overview the prevalence of DHTs, and different DHT sub-
 103 categories, in navigating metabolic disorders in older adults. Second, we seek to identify how are
 104 DHTs used to address metabolic disorders among older adults and by whom. To our knowledge,
 105 this review will be the first to provide an overview of the DHT landscape in metabolic disorders
 106 among older adults.

107

108 *Table 1: Digital Health Technology Ecosystem Categorization*

DHT Cate- gory	Health & Wellness	Patient Monitoring	Care Sup- port	Digital Di- agnostics	Digital Therapeutics
Definition	Disease-agnostic digital health solutions that primarily capture and store general health data and promote healthy living	Digital solu- tions intended to monitor specific health data, which may be interpreted by physician for clinical management	Digital solu- tions intended to help patients better manage their care of a specific dis- ease or medi- cal condition	Validated digi- tal tools and software that deliver a diagnosis or prognosis of a specific dis- ease or medi- cal condition	Health soft- ware intended to treat or alle- viate a specific disease or medical condi- tion by gener- ating and de- livering a medical intervention
Claims	No claims to treat, improve, or diagnose a	May make non-clinical claims to assess patient	May make non-clinical claims to improving	Make a clini- cal claim to diagnose or assess a	Make a clini- cal claim to treat or alle- viate a spe-

	medical condition	data	health adjacent measures (e.g., adherence)	specific disease or medical condition	cific disease or medical condition
--	-------------------	------	--	---------------------------------------	------------------------------------

109 Note: The Digital Health Technology Ecosystem Categorization is adapted from DTx Alliance
 110 and provides a uniform overview of different DHT categories by their intended use. (8)

111 **2 METHODS AND ANALYSIS**

112 For this review, we will adopt the framework outlined by Arksey and O’Malley (1), which in-
 113 volves a five-stage process: (i) formulating the research question, (ii) locating relevant studies,
 114 (iii) choosing studies that meet our criteria, (iv) extracting and organizing data, and (v) compiling
 115 and synthesizing findings. Additionally, we will adhere to the Preferred Reporting Items for Sys-
 116 tematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) (24).

117 **2.1 Identifying Research Questions**

118 Following Arksey and O’Malley’s framework (1), we implemented an iterative process to define
 119 our research questions. We identified gaps in previous scoping reviews (14,19,20), conducted
 120 literature searches, and engaged in discussions with industry and healthcare professionals fo-
 121 cused on promoting metabolic health among older adults. We pose the following questions:

- 122
- 123 RQ1. How prevalent are DHTs in targeting metabolic disorders in older adults?
- 124 RQ2. What specific classes of DHTs have been implemented to address metabolic disorders in
 125 older adults?
- 126 RQ3. By whom are DHTs used in metabolic disorders contexts?
- 127

128 The formulation of these research questions was guided by the PIO (Population, Intervention,
 129 Outcome) concept, as detailed in Table 2, drawing on methodologies from previous studies
 130 (22,25).

131 *Table 2: The PIO framework for the eligibility of studies*

Concept	Determinants
P – Population	Older people (65 or above)
I – Intervention	Digital Health Technologies

O – Outcome	Metabolic Disorders
-------------	---------------------

132

133 **2.2 Identifying relevant studies**

134 The methodology for searching literature in this scoping review is outlined in Table 2, based on
 135 each PIO (Population, Intervention, Outcome) concept. Initial search terms were established
 136 through a preliminary review, particularly by identifying search terms adopted in prior studies on
 137 DHTs, older adults and metabolic health (5,21) (See Table 3). To ensure the search was both pre-
 138 cise and comprehensive, all authors participated in a consensus-building process. The literature
 139 search will span across five major electronic databases: Cochrane, Embase, PubMed, Scopus, and
 140 Web of Science, focusing on publications from January 2014 to January 2024, to capture recent
 141 advancements in technology. For each database, we will use pre-identified terms on DHTS, met-
 142 abolic health, and older adults (See Table 3) to search titles, abstracts, and, when available, Med-
 143 ical Subject Headings (MeSH) terms, or else keywords. Within each PIO concept, the Boolean
 144 operator 'OR' will be used to combine search terms, and then the different concepts will be con-
 145 nected using the 'AND' operator.

146

147 *Table 3: Search terms derived for the PIO framework*

Concept	Search Terms
1: Older people (65 or above) (21)	(Older adult* OR Older person OR Elderly OR 65 or above)
2: DHTs (21)	(Internet OR Telemonitor* OR Teleconsultat* OR Telehealth OR Telecare OR Website* OR Apps* OR Application* OR Digital OR eHealth* OR mHealth* OR Health and Wellness* OR Patient Monitoring* OR Care Support* OR Digital Diagnostics* OR Digital Therapeutics*)
3: Metabolic Disorders (5)	("metabolic health") OR metabolic syndrome[MeSH Major Topic] OR hyperglycemia[MeSH Major Topic] OR insulin resistance[MeSH Major Topic] OR diabetes mellitus, type 2[MeSH Major Topic] OR obesity[MeSH Major Topic] OR dyslipidemias[MeSH Major Topic] OR hyperlipidemias[MeSH Major Topic] OR hypertriglyceridemia[MeSH Major Topic] OR hypercholesterolemia[MeSH Major Topic]

	OR hypertension[MeSH Major Topic]) OR non-alcoholic fatty liver disease[MeSH Major Topic]
--	---

148 *Note:* Search terms adapted from Michels et al. & Cheng et al. (5,21)

149 **2.3 Selection of eligible studies**

150 The process of reviewing titles and abstracts will adhere to the PIO framework (outlined in Table
151 2), using the inclusion and exclusion selection criteria detailed in Table 4 to guarantee that the
152 studies included directly follow our a-priori defined research questions.

153

154 *Table 4: Inclusion and Exclusion Criteria*

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> • Articles published between January 2014 and January 2024 • Original or review research articles Qualitative (qualitative descriptive, phenomenological, ethnographical, grounded theory, realistic evaluation, action research, and so on), quantitative (random controlled trials, cohort study, case-control and cross-sectional, and so on) or reviews (systematic review, meta-analysis, scoping review) • Articles with a primary focus on DHTs for metabolic health • Articles with a primary focus on DHTs for older adults • Older individuals 65 years of age or older (or where the average age of the study sample was 65 years of age or older) who had any metabolic disorders (such as insulin resistance, hyperglycemia, type 2 diabetes, obesity, hyperlipidemia, hypertension, non-alco-holic fatty liver disease (NAFLD), and metabolic syndrome) 	<ul style="list-style-type: none"> • Articles not in English • Articles that do not primarily focus on metabolic syndrome in older adults (aged 65 and above). • Articles which discuss metabolic disorders negligibly or with other comorbidities/health conditions • Articles that mention DHTs briefly or as an insignificant part • Book chapters, commentaries, conference proceedings, editorials, interviews, opinion pieces, proposals, reports, short news, study protocols) • Non-human studies

155

156 **2.4 Charting the data**

157 A form for extracting data will be employed to collect relevant information from every selected
158 article (See Table 5). The process of charting this data will be conducted by hand.

159 *Table 5: Data Charting Form adapted from Schneider et al. (2023) (22)*

Title of study	
DOI	
Year of publication	
Author name/s	
Author location/s	
Study approach	i.e., qualitative or quantitative or mixed method
Type of article	i.e., Case Study, Observational Study, RCT, Review, Trial, Other...
Study location	i.e., where the study was carried out
DHT Category as defined by DTx Alliance	i.e., Digital Therapeutics, Digital Diagnostics, Care Support, Patient Monitoring, Health and Wellness
DHT Use whom	i.e., by who is DHT used (e.g., healthcare provider/researcher/patient)
Outcome measured	i.e., the primary outcome being measured in the study
Notes	

160

161 **2.5 Collating, summarizing, and reporting results**

162 After completing full-text reviews guided by the data extraction charts, we will synthesize the
163 extracted data in descriptive frequency tables. In line with our three research questions, we will
164 first describe the overall frequency of DHTs in studies targeting metabolic disorders in older
165 adults. We will first conduct a comprehensive review of relevant literature and report the preva-
166 lence of DHTs across the studies included in our sample (RQ1). Second, we will describe the
167 frequency of each DHT category (promoting health & wellness, (ii) patient monitoring, (iii) care
168 support, (iv) digital diagnostics, and (v) digital therapeutics (15) in targeting metabolic disorders
169 among older adults (RQ2). Next, we will describe by whom are DHTs used across all the six
170 DHTs categories. By categorizing the different types of DHTs, we aim to provide a comprehen-
171 sive understanding of their utilization in addressing metabolic disorders among older adults and
172 summarize the current DHTs landscape in targeting metabolic disorders.

173 **2.6 Ethics and dissemination**

174 The current review will compile information from existing literature and thus does not require
175 additional ethical clearance. Findings from the scoping review will offer potential relevant in-
176 sights to researchers, policymakers, and healthcare practitioners about the degree to which DHTs
177 are used to target metabolic health orders in older adults and through what relevant approaches,
178 i.e., via health & wellness, patient monitoring, care support, digital diagnostics, and digital thera-

179 peutics. The findings will be shared via a scholarly article in a peer-reviewed journal and pre-
180 sented at academic conferences.

181 **3 DISCUSSION & CONCLUSION**

182 Overall, the proposed scoping review aims to synthesize the prevalence of DHTs and provide
183 insight into DHTs are used to diagnose, manage, and possibly prevent metabolic disorders in old-
184 er adults. This scoping review will contribute to a growing body of literature on DHTs in
185 healthcare by specifically focusing on a key demographic of older adults in metabolic disorder
186 contexts. Compared with prior review articles, this study stands out as the first, to our knowledge,
187 to systematically categorize DHTs specifically for older adults, with a concentrated focus on
188 metabolic disorders. To this end, the scoping review presents an important step in standardizing
189 the literature by adopting the DTx Alliance classification framework (8,9). By adopting the DTx
190 Alliance classification framework, we aim to help standardize terminology and categorization
191 within the literature, thereby potentially improving consistency and comparability across studies.

192 The scoping review presents several significant limitations. As this study encompasses articles
193 featuring a variety of study designs and does not evaluate their quality, it is not designed to re-
194 solve questions regarding specific recommendations of DHTs for managing metabolic disorders
195 in older adults. Additionally, the scope of this review is restricted; articles not written in English
196 or lacking a full-text version will be excluded. We also exclude non-peer-reviewed industry
197 sources, which may overlook cutting-edge developments that have not yet been incorporated into
198 the academic literature. Upon completing the full-text review, we intend to comprehensively pre-
199 sent both the strengths and limitations of our findings. Furthermore, any deviations from the ini-
200 tial protocol will be transparently reported in the final scoping review.

201 Overall, our efforts to synthesize the prevalence and use of DHTs in managing metabolic disor-
202 ders among older adults are expected to highlight essential areas where DHTs are present versus
203 lacking in the existing literature. Specifically, our findings could reveal key areas where DHTs
204 are underutilized among older adults in metabolic health contexts, thus presenting opportunities
205 for increased DHT inclusion and enhancement. Our results may also offer insights into strategic
206 areas for expanding the use of DHTs for older adults. Together, this review will help better un-
207 derstand the DHTs landscape to tackle metabolic health in the older population.

208 **4 REFERENCES**

- 209 1. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International*
210 *Journal of Social Research Methodology*. 2005 Feb 1;8(1):19–32.
- 211 2. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep*. 2018
212 Feb 26;20(2):12.
- 213 3. Chong B, Kong G, Shankar K, Chew HSJ, Lin C, Goh R, et al. The global syndemic of meta-
214 bolic diseases in the young adult population: A consortium of trends and projections from the
215 *Global Burden of Disease 2000–2019*. *Metabolism*. 2023 Apr 1;141:155402.
- 216 4. Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syn-
217 drome. *Curr Hypertens Rep*. 2010 Apr;12(2):113–9.
- 218 5. Michels N, Zouiouich S, Vanderbauwhede B, Vanacker J, Indave Ruiz BI, Huybrechts I.
219 Human microbiome and metabolic health: An overview of systematic reviews. *Obesity Re-*
220 *views*. 2022;23(4):e13409.
- 221 6. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome.
222 *Clin Dermatol*. 2018;36(1):14–20.
- 223 7. Mishra S, Raval M, Kachhawaha AS, Tiwari BS, Tiwari AK. Chapter Eight - Aging: Epige-
224 netic modifications. In: Singh V, Mani I, editors. *Progress in Molecular Biology and Transla-*
225 *tional Science [Internet]*. Academic Press; 2023 [cited 2024 Jan 16]. p. 171–209. (Epigenetics
226 in Health and Disease - Part A; vol. 197). Available from:
227 <https://www.sciencedirect.com/science/article/pii/S1877117323000364>
- 228 8. Digital Therapeutics Alliance [Internet]. [cited 2023 Dec 21]. DTx Evaluation Toolkit. Avail-
229 able from: <https://dtxalliance.org/understanding-dtx/dtx-evaluation-toolkit/>
- 230 9. Health C for D and R. What is Digital Health? FDA [Internet]. 2020 Sep 22 [cited 2023 Dec
231 21]; Available from: [https://www.fda.gov/medical-devices/digital-health-center-](https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health)
232 [excellence/what-digital-health](https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health)
- 233 10. Bhattarai P, Phillips JL. The role of digital health technologies in management of pain in old-
234 er people: An integrative review. *Archives of Gerontology and Geriatrics*. 2017 Jan 1;68:14–
235 24.
- 236 11. Singh S, Bajorek. B. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy.
237 *Pharm Pract (Granada)*. 2014;12(4):489.
- 238 12. Kunonga TP, Spiers GF, Beyer FR, Hanratty B, Boulton E, Hall A, et al. Effects of Digital
239 Technologies on Older People’s Access to Health and Social Care: Umbrella Review. *Journal*
240 *of Medical Internet Research*. 2021 Nov 24;23(11):e25887.
- 241 13. Oh SS, Kim KA, Kim M, Oh J, Chu SH, Choi J. Measurement of Digital Literacy Among
242 Older Adults: Systematic Review. *J Med Internet Res*. 2021 Feb 3;23(2):e26145.

- 243 14. Matthew-Maich N, Harris L, Ploeg J, Markle-Reid M, Valaitis R, Ibrahim S, et al. Designing,
244 Implementing, and Evaluating Mobile Health Technologies for Managing Chronic Condi-
245 tions in Older Adults: A Scoping Review. *JMIR mHealth and uHealth*. 2016 Jun
246 9;4(2):e5127.
- 247 15. Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Metabolic syndrome in the elderly. *Curr*
248 *Diab Rep*. 2006 Jan 1;6(1):64–71.
- 249 16. Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, et al. The Effectiveness of Mo-
250 bile-Health Technologies to Improve Health Care Service Delivery Processes: A Systematic
251 Review and Meta-Analysis. *PLOS Medicine*. 2013 Jan 15;10(1):e1001363.
- 252 17. Liu L, Stroulia E, Nikolaidis I, Miguel-Cruz A, Rios Rincon A. Smart homes and home
253 health monitoring technologies for older adults: A systematic review. *International Journal of*
254 *Medical Informatics*. 2016 Jul 1;91:44–59.
- 255 18. Alhussein G, Hadjileontiadis L. Digital Health Technologies for Long-term Self-management
256 of Osteoporosis: Systematic Review and Meta-analysis. *JMIR Mhealth Uhealth*. 2022 Apr
257 21;10(4):e32557.
- 258 19. De Santis KK, Mergenthal L, Christianson L, Busskamp A, Vonstein C, Zeeb H. Digital
259 Technologies for Health Promotion and Disease Prevention in Older People: Scoping Re-
260 view. *J Med Internet Res*. 2023 Mar 23;25:e43542.
- 261 20. Linn N, Goetzinger C, Regnaud JP, Schmitz S, Dessenne C, Fagherazzi G, et al. Digital
262 Health Interventions among People Living with Frailty: A Scoping Review. *Journal of the*
263 *American Medical Directors Association*. 2021 Sep 1;22(9):1802-1812.e21.
- 264 21. Cheng KKF, Siah RCJ, Ream E, Kanavarar R, Armes J. Protocol for a scoping review of
265 digital health for older adults with cancer and their families. *BMJ Open*. 2020 Aug
266 1;10(8):e038876.
- 267 22. Schneider C, Kowatsch T, Vinay R. Impact of digital assistive technologies on the quality of
268 life for people with dementia: protocol for a scoping review. *BMJ Open*. 2023 Dec
269 13;13(12):e077017.
- 270 23. Taylor J, Walsh S, Kwok W, Pinheiro MB, de Oliveira JS, Hassett L, et al. A scoping review
271 of physical activity interventions for older adults. *International Journal of Behavioral Nutri-*
272 *tion and Physical Activity*. 2021 Jun 30;18(1):82.
- 273 24. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension
274 for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018 Oct
275 2;169(7):467–73.
- 276 25. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a
277 key to evidence-based decisions. *ACP J Club*. 1995;123(3):A12-13.

278
279

280

281 **Footnotes**

282 **Author Statement:** All authors have made substantial intellectual contributions to the develop-
283 ment of this protocol and its revisions. The search question originated with TK, MJ and PH, then
284 was expanded upon by MB and EF. The methodology and design of the review were conceived
285 by PH, guided by suggestions from TK. The development and refinement of the search terms
286 were a collaborative effort between MJ and PH, incorporating feedback and revisions from TK,
287 MB and EF. The final version of the manuscript received unanimous approval from all authors.

288 **Conflicts of interests:** TK and MJ are affiliated with the Centre for Digital Health Interventions,
289 a joint initiative of the Institute for Implementation Science in Health Care, University of Zurich,
290 the Department of Management, Technology, and Economics at ETH Zurich, and the Institute of
291 Technology Management and School of Medicine at the University of St.Gallen, Centre for Digi-
292 tal Health Interventions is funded in part by MavieNext, an Austrian health care provider, CSS, a
293 Swiss health insurer, and MTIP, a growth equity firm. TK is also a co-founder of Pathmate Tech-
294 nologies, a university spin-off company that creates and delivers digital clinical pathways. How-
295 ever, neither CSS, MTIP, nor Pathmate Technologies was involved in this protocol. All other
296 authors have no conflicting interests.

297 **Funding:** This research received no specific grant from any funding agency in the public, com-
298 mercial or not-for-profit sectors.

299 **Patient consent:** Not required.

300 **Provenance and peer review:** Not commissioned; externally peer reviewed.